Synteny develops frontier AI, called MANIFOLD™, to address the challenge of molecular recognition in biology. The platform unifies sequence, structure, and physics data to learn the fundamental laws governing biological cognition. This capability transforms molecular recognition from an intractable problem into programmable biology aimed at decoding biology to end disease.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for disease discovery and precision medicine struggle to effectively analyze the vast complexity of immune repertoire data. Decoding these complex immune signals requires advanced computational tools and expertise, hindering the development of new diagnostics and therapeutics.
Solution
Synteny has developed an AI-powered biotechnology platform designed to analyze immune repertoire data for disease discovery. The platform leverages machine learning algorithms to decode complex immune signals, providing insights into disease mechanisms and potential therapeutic targets. By analyzing patterns within the immune system, Synteny aims to accelerate the development of precision medicine approaches and enhance healthspan. The platform enables researchers and medical professionals to gain a deeper understanding of immune responses and their role in various diseases.
Target Audience
Synteny's primary customers are researchers, pharmaceutical companies, and medical professionals involved in disease discovery and precision medicine.
Features
- AI-driven analysis of immune repertoire sequencing data
- Machine learning models for identifying disease-specific immune signatures
- Advanced algorithms for decoding complex immune signals
- Identification of potential therapeutic targets based on immune repertoire analysis